The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
December 12, 2022
View Complete Issue         Table of Contents 2019 
Mirvetuximab Soravtansine (Elahere) for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Mirvetuximab Soravtansine (Elahere) for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (online only)
December 12, 2022 (Issue: 1665)
Mirvetuximab soravtansine-gynx (Elahere – Immuno-Gen), an antibody-drug conjugate, has received accelerated approval by the FDA for treatment of folate receptor (FR) alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Mirvetuximab Soravtansine (Elahere) for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (online only)
Article code: 1665d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.